Research ArticleOriginal Article
Open Access

Role of venlafaxine in relapse to methamphetamine seeking

Potential treatment option for drug dependence

Yusuf S. Althobaiti
Saudi Medical Journal April 2019, 40 (4) 339-346; DOI: https://doi.org/10.15537/smj.2019.4.23718

References

  1. ↵
    1. United Nations Office on Drugs and Crime
    (2013) World Drug Report 2013 (Vienna (AT):United Nations Office on Drugs and Crime;2013, Naciones Unidas Nueva York).
  2. ↵
    1. Shaham Y,
    2. Shalev U,
    3. Lu L,
    4. de Wit H,
    5. Stewart J
    (2003) The reinstatement model of drug relapse:history, methodology and major findings. Psychopharmacology (Berl) 168:3–20.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Sinha R
    (2007) The role of stress in addiction relapse. Curr Psychiatry Rep 9:388–395.
    OpenUrlCrossRefPubMed
  4. ↵
    1. McDowell DM,
    2. Levin FR,
    3. Seracini AM,
    4. Nunes EV
    (2000) Venlafaxine treatment of cocaine abusers with depressive disorders. Am J Drug Alcohol Abuse 26:25–31.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Streeter CC,
    2. Hennen J,
    3. Ke Y,
    4. Jensen JE,
    5. Sarid-Segal O,
    6. Nassar LE,
    7. et al.
    (2005) Prefrontal GABA levels in cocaine-dependent subjects increase with pramipexole and venlafaxine treatment. Psychopharmacology (Berl) 182:516–526.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Magalas Z,
    2. De Vry J,
    3. Tzschentke TM
    (2005) The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats. Eur J Pharmacol 528:103–109.
    OpenUrlPubMed
  7. ↵
    1. Lu L,
    2. Su W-J,
    3. Yue W,
    4. Ge X,
    5. Su F,
    6. Pei G,
    7. et al.
    (2001) Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor. Life Sciences 69:37–46.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Milanese M,
    2. Tardito D,
    3. Musazzi L,
    4. Treccani G,
    5. Mallei A,
    6. Bonifacino T,
    7. et al.
    (2013) Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes. BMC Neurosci 14:75.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Farrell MR,
    2. Schoch H,
    3. Mahler SV
    (2018) Modeling cocaine relapse in rodents:Behavioral considerations and circuit mechanisms. Prog Neuropsychopharmacol Biol Psychiatry 87:33–47.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Kufahl PR,
    2. Watterson LR,
    3. Nemirovsky NE,
    4. Hood LE,
    5. Villa A,
    6. Halstengard C,
    7. et al.
    (2013) Attenuation of methamphetamine seeking by the mGluR2/3 agonist LY379268 in rats with histories of restricted and escalated self-administration. Neuropharmacology 66:290–301.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. McKetin R,
    2. Dean OM,
    3. Baker AL,
    4. Carter G,
    5. Turner A,
    6. Kelly PJ,
    7. et al.
    (2017) A potential role for N-acetylcysteine in the management of methamphetamine dependence. Drug Alcohol Rev 36:153–159.
    OpenUrl
  12. ↵
    1. He Z,
    2. Chen Y,
    3. Dong H,
    4. Su R,
    5. Gong Z,
    6. Yan L
    (2014) Inhibition of vesicular glutamate transporters contributes to attenuate methamphetamine-induced conditioned place preference in rats. Behav Brain Res 267:1–5.
    OpenUrl
  13. ↵
    1. Abulseoud OA,
    2. Miller JD,
    3. Wu J,
    4. Choi D-S,
    5. Holschneider DP
    (2012) Ceftriaxone upregulates the glutamate transporter in medial prefrontal cortex and blocks reinstatement of methamphetamine seeking in a condition place preference paradigm. Brain Res 1456:14–21.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Muth EA,
    2. Haskins JT,
    3. Moyer JA,
    4. Husbands GE,
    5. Nielsen ST,
    6. Sigg EB
    (1986) Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 35:4493–4497.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Richelson E
    (1996) Synaptic effects of antidepressants. J Clin Psychopharmacol 16:1S–7S.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Nakagawa T,
    2. Fujio M,
    3. Ozawa T,
    4. Minami M,
    5. Satoh M
    (2005) Effect of MS-153, a glutamate transporter activator, on the conditioned rewarding effects of morphine, methamphetamine and cocaine in mice. Behav Brain Res 156:233–239.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Fujio M,
    2. Nakagawa T,
    3. Sekiya Y,
    4. Ozawa T,
    5. Suzuki Y,
    6. Minami M,
    7. et al.
    (2005) Gene transfer of GLT-1, a glutamate transporter, into the nucleus accumbens shell attenuates methamphetamine- and morphine-induced conditioned place preference in rats. Eur J Neurosci 22:2744–2754.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Zeng L,
    2. Tao Y,
    3. Hou W,
    4. Zong L,
    5. Yu L
    (2018) Electro-acupuncture improves psychiatric symptoms, anxiety and depression in methamphetamine addicts during abstinence:A randomized controlled trial. Medicine (Baltimore) 97:e11905.
    OpenUrl
  19. ↵
    1. Davis JP,
    2. Berry D,
    3. Dumas TM,
    4. Ritter E,
    5. Smith DC,
    6. Menard C,
    7. et al.
    (2018) Substance use outcomes for mindfulness based relapse prevention are partially mediated by reductions in stress:Results from a randomized trial. J Subst Abuse Treat 91:37–48.
    OpenUrl
  20. ↵
    1. Wang K,
    2. Burton CL,
    3. Pachankis JE
    (2018) Depression and substance use:Towards the development of an emotion regulation model of stigma coping. Subst Use Misuse 53:859–866.
    OpenUrl
  21. ↵
    1. Musazzi L,
    2. Milanese M,
    3. Farisello P,
    4. Zappettini S,
    5. Tardito D,
    6. Barbiero VS,
    7. et al.
    (2010) Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex:the dampening action of antidepressants. PloS One 5:e8566.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Caprioli D,
    2. Justinova Z,
    3. Venniro M,
    4. Shaham Y
    (2018) Effect of novel allosteric modulators of metabotropic glutamate receptors on drug self-administration and relapse:a review of preclinical studies and their clinical implications. Biol Psychiatry 84:180–192.
    OpenUrl
  23. ↵
    1. Rose CR,
    2. Ziemens D,
    3. Untiet V,
    4. Fahlke C
    (2018) Molecular and cellular physiology of sodium-dependent glutamate transporters. Brain Res Bull 136:3–16.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Olivero G,
    2. Grilli M,
    3. Vergassola M,
    4. Bonfiglio T,
    5. Padolecchia C,
    6. Garrone B,
    7. et al.
    (2018) 5-HT2A-mGlu2/3 receptor complex in rat spinal cord glutamatergic nerve endings:A 5-HT2A to mGlu2/3 signalling to amplify presynaptic mechanism of auto-control of glutamate exocytosis. Neuropharmacology 133:429–439.
    OpenUrl
  25. ↵
    1. Gao JT,
    2. Jordan CJ,
    3. Bi GH,
    4. He Y,
    5. Yang HJ,
    6. Gardner EL,
    7. et al.
    (2018) Deletion of the type 2 metabotropic glutamate receptor increases heroin abuse vulnerability in transgenic rats. Neuropsychopharmacology 43:2615.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Zhao Y,
    2. Dayas CV,
    3. Aujla H,
    4. Baptista MA,
    5. Martin-Fardon R,
    6. Weiss F
    (2006) Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci 26:9967–9974.
    OpenUrlAbstract/FREE Full Text
    1. Baptista MA,
    2. Martin-Fardon R,
    3. Weiss F
    (2004) Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement:comparison between cocaine and a potent conventional reinforcer. J Neurosci 24:4723–4727.
    OpenUrlAbstract/FREE Full Text
    1. Bossert JM,
    2. Busch RF,
    3. Gray SM
    (2005) The novel mGluR2/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking. Neuroreport 16:1013–1016.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Kufahl PR,
    2. Martin-Fardon R,
    3. Weiss F
    (2011) Enhanced sensitivity to attenuation of conditioned reinstatement by the mGluR2/3 agonist LY379268 and increased functional activity of mGluR2/3 in rats with a history of ethanol dependence. Neuropsychopharmacology 36:2762–2773.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Stoops WW
    (2006) Aripiprazole as a potential pharmacotherapy for stimulant dependence:human laboratory studies with d-amphetamine. Exp Clin Psychopharmacol 14:413.
    OpenUrlCrossRefPubMed
    1. Heinzerling KG,
    2. Shoptaw S,
    3. Peck JA,
    4. Yang X,
    5. Liu J,
    6. Roll J,
    7. et al.
    (2006) Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence. Drug Alcohol Depend 85:177–184.
    OpenUrlCrossRefPubMedWeb of Science
    1. Fechtner RD,
    2. Khouri AS,
    3. Figueroa E,
    4. Ramirez M,
    5. Federico M,
    6. Dewey SL,
    7. et al.
    (2006) Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin:ocular safety pilot results. Arch Ophthalmol 124:1257–1262.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Shoptaw S,
    2. Huber A,
    3. Peck J,
    4. Yang X,
    5. Liu J,
    6. Dang J,
    7. et al.
    (2006) Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 85:12–18.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. McElhiney MC,
    2. Rabkin JG,
    3. Rabkin R,
    4. Nunes EV
    (2009) Provigil (modafinil) plus cognitive behavioral therapy for methamphetamine use in HIV+gay men:a pilot study. Am J Drug Alcohol Abuse 35:34–37.
    OpenUrlCrossRefPubMedWeb of Science
  35. ↵
    1. McGregor C,
    2. Srisurapanont M,
    3. Mitchell A,
    4. Wickes W,
    5. White JM
    (2008) Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal:a comparison of mirtazapine and modafinil with treatment as usual. J Subst Abuse Treat 35:334–342.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Reichel CM,
    2. See RE
    (2010) Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse. Psychopharmacology (Berl) 210:337–346.
    OpenUrlCrossRef
  37. ↵
    1. Tahsili-Fahadan P,
    2. Carr GV,
    3. Harris GC,
    4. Aston-Jones G
    (2010) Modafinil blocks reinstatement of extinguished opiate-seeking in rats:mediation by a glutamate mechanism. Neuropsychopharmacology 35:2203–2210.
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Deroche-Gamonet V,
    2. Darnaudery M,
    3. Bruins-Slot L,
    4. Piat F,
    5. Le Moal M,
    6. Piazza P
    (2002) Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology 161:387–395.
    OpenUrlCrossRefPubMed
    1. Stoops WW,
    2. Lile JA,
    3. Fillmore MT,
    4. Glaser PE,
    5. Rush CR
    (2005) Reinforcing effects of modafinil:influence of dose and behavioral demands following drug administration. Psychopharmacology 182:186–193.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Bernardi RE,
    2. Lewis JR,
    3. Lattal KM,
    4. Berger SP
    (2009) Modafinil reinstates a cocaine conditioned place preference following extinction in rats. Behav Brain Res 204:250–253.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section